Evolus (EOLS) Non-Current Deferred Tax Liability (2017 - 2026)
Evolus' (EOLS) quarterly Non-Current Deferred Tax Liability came in at $23000.0 in Q1 2026, up 1050.0% YoY from $2000.0 in Q1 2025, and down 17.86% on a QoQ basis from $28000.0 in Q4 2025.
Evolus (EOLS) Non-Current Deferred Tax Liability (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $23000.0 in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 1050.0% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (up 1050.0% YoY) and the FY2025 annual result came in at $28000.0, up 366.67% from the prior year.
- Non-Current Deferred Tax Liability eased to $23000.0 in Q1 2026, from $28000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $32000.0 in Q1 2024 to a low of $2000.0 in Q1 2025.
- A 5-year average of $22625.0 and a median of $23000.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability tumbled 93.75% — and 2026, when it surged 1050.0%.
- Tracing EOLS's Non-Current Deferred Tax Liability over 5 years: stood at $22000.0 in 2022, then climbed by 22.73% to $27000.0 in 2023, then tumbled by 77.78% to $6000.0 in 2024, then jumped by 366.67% to $28000.0 in 2025, then retreated by 17.86% to $23000.0 in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $23000.0 (Q1 2026), $28000.0 (Q4 2025), and $21000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15,000.00 |
| Jun 30, 2026 | 15,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |